No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 299 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR “If there is an under-representation of ethnic minority communities, there will... September 18, 2020 FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma August 24, 2021 How People With Advanced Cancer Can Find Meaning Toward the End... July 25, 2023 EMA Recommends Extension of Indications for Venetoclax May 14, 2021 Load more HOT NEWS Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival... First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone... Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... Cancer Research UK report highlights stark cancer inequalities across Scotland
